United Bank (Virginia)’s Teva Pharmaceuticals TEVA Stock Holding History

United Bank (Virginia)’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-7,322	Closed	-$337K	–	50
2016 Q3	$337K	Sell	7,322 -10,647	-59%	-$555K	0.36%	45
2016 Q2	$903K	Buy	17,969 +4,981	+38%	+$265K	0.89%	37
2016 Q1	$695K	Buy	12,988 +7,673	+144%	+$450K	0.7%	38
2015 Q4	$349K	Buy	+5,315	New	+$328K	0.42%	42

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

United Bank (Virginia)'s TEVA Position: Q4 2016 in Review

United Bank (Virginia) sold out of Teva Pharmaceuticals (TEVA) in Q4 2016, closing a stake of 7,322 shares — an estimated $337K sold.

United Bank (Virginia) first reported a position in TEVA in Q4 2015 and held it in 4 quarters. The position peaked at $903K in Q2 2016. 737 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

United Bank (Virginia) reported no remaining Teva Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
United Bank (Virginia) sold 7,322 Teva Pharmaceuticals shares in Q4 2016, an estimated $337K.
United Bank (Virginia) first reported a position in Teva Pharmaceuticals in Q4 2015 and held it in 4 quarters.
United Bank (Virginia)'s Teva Pharmaceuticals position peaked at $903K in Q2 2016.
737 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on United Bank (Virginia)'s 13F filing for Q4 2016, filed 30 Jan 2017.